You are here

FDA Declines to Approve Generic Version of Advair Diskus––for Now

Mylan keeps reason for rejection under wraps

Mylan has reported on the status of its abbreviated new drug application with the FDA for its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder). The company states that it has received a complete response letter (CRL) from the FDA and is in the process of reviewing the agency’s comments.

Mylan provided no details regarding the FDA’s concerns or how long the product might be delayed.

The CRL has given GlaxoSmithKline additional time to sell Advair Diskus without competition from a cheaper generic. According to Reuters, Advair has generated more than $1 billion in sales each year since 2001.

Another generic version of Advair––from Hikma Pharmaceuticals––is awaiting an FDA approval decision by May 10.

Sources: Mylan; March 29, 2017; and Reuters; March 29, 2017.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs